Skip to main content
Sun Pharma Advanced Research Company Ltd. logo

Sun Pharma Advanced Research Company Ltd. — Investor Relations & Filings

Ticker · SPARC ISIN · INE232I01014 LEI · 3358001Y3QHHUNROTJ51 BSE.NS Professional, scientific and technical activities
Open in API
Filings indexed 638 across all filing types
Latest filing 2024-12-24 Call Transcript
Country IN India
Listing BSE.NS SPARC

About Sun Pharma Advanced Research Company Ltd.

https://www.sparc.life

Sun Pharma Advanced Research Company Ltd. (SPARC) is a clinical-stage biopharmaceutical company dedicated to the research and development of innovative pharmaceutical products and drug delivery systems. SPARC focuses on creating new chemical entities (NCEs), new biological entities (NBEs), and reformulated products that address significant unmet medical needs. The company utilizes proprietary technology platforms, such as WrapMatrix and Nanotecton, to enhance the efficacy and safety of treatments. Its research pipeline primarily targets therapeutic areas including oncology, neurodegeneration, and ophthalmology. SPARC advances candidates through various stages of clinical trials to provide value-added medicines and novel therapeutic solutions for complex health conditions, leveraging its expertise in formulation and clinical development to improve patient outcomes globally.

Recent filings

Filing Released Lang Actions
Investor Presentation
Call Transcript Classification · 100% confidence The document is a detailed transcript of an investor conference call held by Sun Pharma Advanced Research Company Ltd. on December 19, 2024. It includes management presentations, discussions on clinical programs, R&D pipeline updates, and Q&A sessions. The text explicitly mentions it is a transcript of the investor call, and the content is consistent with a conference call transcript, including moderator instructions, management introductions, and detailed program updates. There are no indications that this is a financial report, earnings release, or regulatory filing. The document length (15,000 characters) and detailed content confirm it is not a brief announcement or a report publication notice. Therefore, the appropriate classification is Call Transcript (CT).
2024-12-24 English
Investor Presentation
Investor Presentation Classification · 100% confidence The document is a detailed investor presentation from Sun Pharma Advanced Research Company Ltd. dated December 19, 2024. It includes an agenda, clinical program updates, R&D pipeline information, strategy and priorities, and detailed scientific and market data. The text explicitly mentions 'Investor Presentation' in the subject line and throughout the document. It also references a conference call and provides dial-in details, which is typical for investor presentations. The content is focused on business strategy, clinical updates, and market outlook rather than financial statements or regulatory filings. The document length is substantial (15,000 characters), indicating it is the full presentation, not just an announcement or a brief summary. Therefore, the appropriate classification is Investor Presentation (IP).
2024-12-19 English
Press Release
Capital/Financing Update Classification · 95% confidence The document is a press release announcing the signing of a binding Letter of Intent (LOI) between SPARC, UCSF, and Tiller Therapeutics regarding a pre-clinical oncology asset and associated intellectual property. It is an announcement of a corporate transaction and partnership, not a detailed financial report, earnings release, or regulatory filing. The content focuses on the business development and strategic partnership rather than financial results or governance changes. Therefore, it fits best under Capital/Financing Update (CAP) as it relates to equity stake and licensing agreements, which are financing-related activities.
2024-12-17 English
Press Release
Investor Presentation Classification · 95% confidence The document is a notification from Sun Pharma Advanced Research Company Ltd. about an upcoming Management Presentation and conference call to update on clinical programs and R&D pipeline. It includes dial-in details for the audio conference and a link to access the presentation on the date of the call. The document does not contain actual financial data or detailed financial reports but is an announcement of an investor presentation event. The document length is 4062 characters, which is relatively short and consistent with an announcement rather than a full report or transcript. Therefore, this document fits the category of an Investor Presentation (IP) announcement or notification rather than the presentation itself or a transcript. Given the content and context, the best classification is Investor Presentation (IP).
2024-12-14 English
Issue of Duplicate Share Certificate
Regulatory Filings Classification · 95% confidence The document is an intimation under Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. It provides details of issuance of duplicate share certificates to shareholders. This is a regulatory announcement related to share certificate replacement and does not contain financial data, management discussion, or report content. It is not a report or financial statement but a compliance notification to stock exchanges. Therefore, it fits best under Regulatory Filings (RNS). The document length is short and it is a formal notification rather than a report or announcement of voting results or capital changes.
2024-12-05 English
Spurt in Volume
Regulatory Filings Classification · 95% confidence The document is a letter addressed to the National Stock Exchange of India regarding compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. It confirms that all required disclosures have been made and that there is no undisclosed information. The document is a regulatory compliance clarification and does not contain financial data, report content, or detailed disclosures itself. It is short (1331 characters) and serves as a formal regulatory communication rather than a financial report or announcement of a report. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements and compliance confirmations.
2024-11-26 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.